Altimmune (ALT)
(Delayed Data from NSDQ)
$7.79 USD
+0.22 (2.91%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.80 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Altimmune, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -88.45 | -84.71 | -97.09 | -49.04 | -20.52 |
Depreciation/Amortization & Depletion | -1.99 | -0.21 | 0.55 | 0.30 | 1.39 |
Net Change from Assets/Liabilities | -8.27 | 14.11 | -0.25 | -4.51 | 1.82 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 22.91 | 8.22 | 18.55 | 18.82 | 7.71 |
Net Cash From Operating Activities | -75.81 | -62.59 | -78.24 | -34.44 | -9.60 |
Property & Equipment | -0.05 | -0.13 | -12.12 | -0.20 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 13.78 | -73.27 | 99.83 | -71.75 | -28.26 |
Other Investing Activities | 0.00 | 0.00 | -0.19 | -0.14 | -0.03 |
Net Cash from Investing Activities | 13.73 | -73.40 | 87.52 | -72.09 | -28.29 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 86.93 | 56.78 | 65.22 | 213.49 | 12.70 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -0.09 | 0.00 | 0.00 | 0.00 | -0.29 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.73 | 0.00 | -0.12 | 0.00 | 0.13 |
Net Cash from Financing Activities | 86.11 | 56.78 | 65.10 | 213.49 | 12.53 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 24.03 | -79.20 | 74.38 | 106.96 | -25.36 |
Cash at Beginning of Period | 111.13 | 190.34 | 115.95 | 9.00 | 34.35 |
Cash at End of Period | 135.16 | 111.13 | 190.33 | 115.95 | 9.00 |
Diluted Net EPS | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 |
Fiscal Year End for Altimmune, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -49.03 | -24.39 | -88.45 | -56.81 | -36.14 |
Depreciation/Amortization & Depletion | -1.88 | -0.88 | -1.99 | -1.41 | -0.86 |
Net Change from Assets/Liabilities | 8.41 | 5.26 | -8.27 | -9.09 | -7.12 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.04 | 3.66 | 22.91 | 8.04 | 5.33 |
Net Cash From Operating Activities | -34.47 | -16.36 | -75.81 | -59.28 | -38.79 |
Property & Equipment | 0.00 | 0.00 | -0.05 | -0.05 | -0.05 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -43.22 | -39.52 | 13.78 | 21.74 | 17.34 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -43.22 | -39.52 | 13.73 | 21.69 | 17.29 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.54 | 0.34 | 86.93 | 14.14 | 13.55 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | -0.09 | -0.09 | -0.09 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.84 | -0.60 | -0.73 | -0.70 | -0.70 |
Net Cash from Financing Activities | -0.31 | -0.26 | 86.11 | 13.35 | 12.76 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -77.99 | -56.14 | 24.03 | -24.24 | -8.74 |
Cash at Beginning of Period | 135.16 | 135.16 | 111.13 | 111.13 | 111.13 |
Cash at End of Period | 57.17 | 79.02 | 135.16 | 86.90 | 102.39 |
Diluted Net EPS | -0.35 | -0.34 | -0.55 | -0.39 | -0.32 |